Skip to main content
SpringerLink
Log in

Bevacizumab plus CCNU bei Rezidiv-Glioblastom

Der neue Standard?

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Originalie

  • Taal W et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Universitätsspital Zürich, Zürich, Schweiz

    Michael Weller (Direktor)

Authors
  1. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Weller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weller, M. Der neue Standard?. Info Onkol. 18, 18 (2015). https://doi.org/10.1007/s15004-015-0804-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-0804-y

Schlüsselwörter

Search

Navigation